Peter R. Galle

Research interests

Publications

• EASL Clinical Practice Guidelines on the management of hepatocellular carcinoma

  Journal of Hepatology · 2024 · https://doi.org/10.1016/j.jhep.2024.08.028

• Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma

  Annals of Oncology · 2024 · https://doi.org/10.1016/j.annonc.2024.02.005

• Neutralizing GDF-15 can overcome anti-PD-1 and anti-PD-L1 resistance in solid tumours

  Nature · 2024 · https://doi.org/10.1038/s41586-024-08305-z

• The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 24th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2022

  ESMO Open · 2023 · https://doi.org/10.1016/j.esmoop.2023.101567

• Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial

  The Lancet Oncology · 2023 · https://doi.org/10.1016/s1470-2045(23)00469-2

• Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child‐Pugh A and B cirrhosis: A real‐world study

  Hepatology · 2022 · https://doi.org/10.1002/hep.32468

• Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma

  NEJM Evidence · 2022 · https://doi.org/10.1056/evidoa2100070

• Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma

  Journal of Hepatology · 2021 · https://doi.org/10.1016/j.jhep.2021.11.030

• Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial

  The Lancet Oncology · 2021 · https://doi.org/10.1016/s1470-2045(21)00151-0

• Low Accuracy of FIB-4 and NAFLD Fibrosis Scores for Screening for Liver Fibrosis in the Population

  Clinical Gastroenterology and Hepatology · 2021 · https://doi.org/10.1016/j.cgh.2021.12.034

• BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update

  Journal of Hepatology · 2021 · https://doi.org/10.1016/j.jhep.2021.11.018

• Systemic treatment of hepatocellular carcinoma: An EASL position paper

  Journal of Hepatology · 2021 · https://doi.org/10.1016/j.jhep.2021.07.004

• IMbrave150: Updated overall survival (OS) data from a global, randomized, open-label phase III study of atezolizumab (atezo) + bevacizumab (bev) versus sorafenib (sor) in patients (pts) with unresectable hepatocellular carcinoma (HCC).

  Journal of Clinical Oncology · 2021 · https://doi.org/10.1200/jco.2021.39.3_suppl.267

• Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma

  New England Journal of Medicine · 2020 · https://doi.org/10.1056/nejmoa1915745

• Transient elastography for screening of liver fibrosis: Cost-effectiveness analysis from six prospective cohorts in Europe and Asia

  Journal of Hepatology · 2019 · https://doi.org/10.1016/j.jhep.2019.08.019

• Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial

  The Lancet Oncology · 2019 · 10.1016/s1470-2045(18)30937-9

• IMbrave150: Efficacy and safety results from a ph III study evaluating atezolizumab (atezo) + bevacizumab (bev) vs sorafenib (Sor) as first treatment (tx) for patients (pts) with unresectable hepatocellular carcinoma (HCC)

  Annals of Oncology · 2019 · https://doi.org/10.1093/annonc/mdz446.002

• Biology and significance of alpha‐fetoprotein in hepatocellular carcinoma

  Liver International · 2019 · https://doi.org/10.1111/liv.14223

• EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma

  Journal of Hepatology · 2018 · https://doi.org/10.1016/j.jhep.2018.03.019

• Role of the GALAD and BALAD-2 Serologic Models in Diagnosis of Hepatocellular Carcinoma and Prediction of Survival in Patients

  Clinical Gastroenterology and Hepatology · 2016 · https://doi.org/10.1016/j.cgh.2015.12.042

• Elafibranor, an Agonist of the Peroxisome Proliferator−Activated Receptor−α and −δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening

  Gastroenterology · 2016 · 10.1053/j.gastro.2016.01.038

• Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma

  Journal of Hepatology · 2014 · 10.1016/j.jhep.2014.01.021

• Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trial

  Journal of Hepatology · 2012 · 10.1016/j.jhep.2012.06.014

• Sorafenib in Advanced Hepatocellular Carcinoma

  New England Journal of Medicine · 2008 · https://doi.org/10.1056/nejmoa0708857

• Simplified criteria for the diagnosis of autoimmune hepatitis†

  Hepatology · 2008 · https://doi.org/10.1002/hep.22322

• Pregnancy in Autoimmune Hepatitis: Outcome and Risk Factors

  The American Journal of Gastroenterology · 2006 · https://doi.org/10.1111/j.1572-0241.2006.00479.x

• Colorectal cancer

  The Lancet · 2005 · 10.1016/s0140-6736(05)17706-x

• Cutting Edge: TGF-β Induces a Regulatory Phenotype in CD4+CD25− T Cells through Foxp3 Induction and Down-Regulation of Smad7

  The Journal of Immunology · 2004 · 10.4049/jimmunol.172.9.5149

• Confocal laser endoscopy for diagnosing intraepithelial neoplasias and colorectal cancer in vivo

  Gastroenterology · 2004 · 10.1053/j.gastro.2004.06.050

• CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes

  Journal of Clinical Investigation · 2003 · 10.1172/jci16432

• Methylene blue-aided chromoendoscopy for the detection of intraepithelial neoplasia and colon cancer in ulcerative colitis

  Gastroenterology · 2003 · 10.1053/gast.2003.50146

• Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: Evidence in Crohn disease and experimental colitis in vivo

  Nature Medicine · 2000 · 10.1038/75068

• p53 Activates the CD95 (APO-1/Fas) Gene in Response to DNA Damage by Anticancer Drugs

  The Journal of Experimental Medicine · 1998 · 10.1084/jem.188.11.2033

• Drug-induced apoptosis in hepatoma cells is mediated by the CD95 (APO-1/Fas) receptor/ligand system and involves activation of wild-type p53.

  Journal of Clinical Investigation · 1997 · 10.1172/jci119174

• Lymphocyte apoptosis induced by CD95 (APO–1/Fas) ligand–expressing tumor cells — A mechanism of immune evasion?

  Nature Medicine · 1996 · 10.1038/nm1296-1361

Current projects

No projects listed.